Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pulse Biosciences ( (PLSE) ) is now available.
On March 3, 2026, Pulse Biosciences posted an updated investor presentation outlining summary financial information and new details on its next generation nPulse cardiac catheter under development. The deck highlights the company’s strengthened focus on its EP cardio ablation product and clinical development, following what it described as unprecedented clinical outcomes data in its EU feasibility study, and will be used in upcoming communications with investors and analysts.
The information in the investor presentation is current as of March 2026 and is characterized as summary in nature, with the company noting it may update the material from time to time as required. While the filing clarifies that the presentation is furnished rather than filed for securities law purposes, the move underscores Pulse Biosciences’ effort to spotlight its cardiac ablation technology and clinical results to the market and other stakeholders.
The most recent analyst rating on (PLSE) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held back primarily by very weak financial performance (minimal revenue, large losses, and accelerating cash burn). Offsetting factors include constructive technical positioning and an earnings narrative showing strong clinical/regulatory momentum, but valuation support is limited given ongoing unprofitability and no dividend.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a medical technology company focused on electrophysiology and cardiac ablation solutions. Its development pipeline includes the next generation nPulse cardiac catheter, targeting the EP cardio ablation market with an emphasis on clinical performance and feasibility in European studies.
Average Trading Volume: 316,136
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.28B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.